Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 8,121–8,140 of 17,964 drug recalls

Drug Recall Terminated Historical recordClass II

Losartan Potassium Tablets USP 50 mg 50 Tablets (5x10) Unit Dose boxes, Rx Only, Manufactured for: AvKARE Inc. Pulaski, TN 38478 ---- NDC 50268-517-15

by AVKARE Inc.

Reason
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified
Recall initiated
March 5, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 90 count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-0052-10

by Macleods Pharma Usa Inc

Reason
CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.
Recall initiated
February 21, 2019
Reported by FDA
March 27, 2019
Distribution
NJ, NY, FL

View recall →

Drug Recall Ongoing Historical recordClass II

Valsartan Tablets USP 160 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-572-90

by Aurobindo Pharma USA Inc.

Reason
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Recall initiated
December 31, 2018
Reported by FDA
March 27, 2019
Distribution
Product was distributed to major distribution chains throughout the United States.

View recall →

Drug Recall Ongoing Historical recordClass II

Valsartan Tablets USP 80 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-571-90

by Aurobindo Pharma USA Inc.

Reason
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Recall initiated
December 31, 2018
Reported by FDA
March 27, 2019
Distribution
Product was distributed to major distribution chains throughout the United States.

View recall →

Drug Recall Ongoing Historical recordClass II

Valsartan Tablets USP 40 mg, 30 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-570-30

by Aurobindo Pharma USA Inc.

Reason
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Recall initiated
December 31, 2018
Reported by FDA
March 27, 2019
Distribution
Product was distributed to major distribution chains throughout the United States.

View recall →

Drug Recall Ongoing Historical recordClass II

Amlodipine and Valsartan Tablets USP 10mg/160mg, 30 count bottles, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ Manufactured by: Aurobindo Pharma Limited, India --- NDC 65862-739-30

by Aurobindo Pharma USA Inc.

Reason
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Recall initiated
December 31, 2018
Reported by FDA
March 27, 2019
Distribution
Product was distributed to major distribution chains throughout the United States.

View recall →

Drug Recall Ongoing Historical recordClass II

Valsartan Tablets USP 320 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-573-90

by Aurobindo Pharma USA Inc.

Reason
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Recall initiated
December 31, 2018
Reported by FDA
March 27, 2019
Distribution
Product was distributed to major distribution chains throughout the United States.

View recall →

Drug Recall Terminated Historical recordClass II

Phenylephrine HCl, 1,200 mcg in 0.9% Sodium Chloride, QS 10 mL Injectable Solution 1,200 mcg/10 mL (120 mcg per mL), Sterile single use syringe, NDC: 42852-882-61 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Heparin 10 Units/10 mL 10 Units in 0.45% Sodium Chloride, QS 10 mL, Injectable Solution, Dwell, 10mL Sterile single use syringe, NDC: 42852-725-61 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Phenylephrine HCl, 800 mcg in 0.9% Sodium Chloride, QS 10 mL Injectable Solution, 800 mcg/10 mL (80 mcg per mL), 10mL Sterile single use syringe, NDC: 42852-865-61 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

2% Lidocaine HCl Injectable Solution, 100 mg/5 mL (20 mg per mL), 5mL Sterile single use syringe, NDC: 42852-011-67 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Glycopyrrolate 0.6 mg/3 mL (0.2 mg per mL) Injectable Solution, 3 mL Sterile single use syringe, For IV or IM use, NDC: 42852-828-22 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Neostigmine Methylsulfate Injection Solution 5 mg/5mL (1 mg per mL), 5mL Sterile single use syringe, For IV use only, NDC: 42852-829-67 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Phenylephrine HCl, 500 mcg in 0.9% Sodium Chloride, QS 5 mL Injectable Solution 500 mcg/5 mL (100 mcg per mL), 5mL Sterile single use syringe, NDC: 42852-830-67 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Midazolam Benzodiazepine 50 mg/50 mL (1 mg/mL) Injectable Solution, Midazolam HCl 0.9% Sodium Chloride, QS, Sterile single use bag, NDC: 42852-401-05 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

HYDROmorphone HCl 1 mg in 0.9% Sodium Chloride, QS 5 mL Injectable Solution 1 mg/5 mL (0.2 mg per mL), Sterile single use syringe, NDC: 42852-289-67 Avella of Houston 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404

by Advanced Pharma Inc.

Reason
Lack of Assurance of Sterility
Recall initiated
March 13, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-788-20

by Mylan Institutional, Inc. (d.b.a. UDL Laboratories)

Reason
Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval.
Recall initiated
January 18, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass III

Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100 tablets (10 blister cards of 10 tablets each), Rx only, Manufactured in Israel By: Teva Pharmaceutical Ind. Ltd. Jerusalem, 9777402, Israel, Manufactured for: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0093-3008-93

by Teva Pharmaceuticals USA

Reason
Subpotent Drug.
Recall initiated
March 11, 2019
Reported by FDA
March 27, 2019
Distribution
Nationwide in the United States.

View recall →

Drug Recall Ongoing Historical recordClass II

Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ, Manufactured by: Aurolife Pharma LLC, Dayton, NJ ---- NDC 52343-122-30

by Rising Pharmaceuticals, Inc.

Reason
CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products
Recall initiated
March 7, 2019
Reported by FDA
March 27, 2019
Distribution
Product was distributed to 6 major distributors who may have further distributed the product throughout the United States.

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium Tablets, USP, 100 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-579-54

by Legacy Pharmaceutical Packaging LLC

Reason
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Recall initiated
March 1, 2019
Reported by FDA
March 27, 2019
Distribution
Wal-Mart distribution centers in AR, CA, GA, IN and MD

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.